<DOC>
	<DOCNO>NCT03065985</DOCNO>
	<brief_summary>This study ass endoscopic ultrasound radiofrequency application patient inoperable pancreatic cancer chemotherapy confers survival benefit compare patient receive best medical care chemotherapy .</brief_summary>
	<brief_title>EUS-RFA Inoperable Pancreatic Ductal Adenocarcinoma .</brief_title>
	<detailed_description>Prospective randomise clinical study patient adenocarcinoma pancreas . Patients randomise 1:1 . Patients treatment group receive standard chemotherapy plus 3 radiofrequency ablation procedure , one month apart . Patients control group receive standard chemotherapy best medical care .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Patients 18 year age A cytological/ histological diagnosis inoperable PDAC base multidisciplinary review crosssectional imaging cytology/ histology result . Patients deem unfit surgical resection PDAC ; subject fit surgical resection , decline surgery also consider study PDAC patient present jaundice consider successful biliary drainage ( bilirubin &lt; 50umol/L ) Patients ought fit enough consider study ( ECOG performance status 0 , 1 2 ) Patients commence chemotherapy exclude study Patients capable give informed consent Negative blood pregnancy test woman childbearing potential Willingness ability comply protocol requirement include scheduled visit , treatment plan , laboratory test study procedure . ECOG performance status 3 4 Life expectancy le 3 month Prior investigational drug within last 30 day Grade &gt; 1 treatmentrelated toxicity ( exclude alopaecia ) time screen Patients clinically significant cancer ascites Known infection human immunodeficiency virus ( HIV ) Patient central nervous system ( CNS ) metastasis Major surgery within last 30 day Patients sepsis , obstructive jaundice encephalopathy Evidence spontaneous bacterial peritonitis renal failure Pregnant lactate woman Any condition ( e.g. , know suspected poor compliance , etc . ) , judgment investigator , may affect participant 's ability follow protocol specific procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>